Peter Keating
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter Keating has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Cambrosio
Department of Social Studies of Medicine, McGill University, Montreal, QC, Canada
30 shared publications Alberto Cambrosio
Department of Social Studies of Medicine, McGill University, Montreal, Canada
10 shared publications- Nicole Christine Nelson
University of Wisconsin–Madison
3 shared publications - Etienne Vignola-Gagné
Science-Metrix
2 shared publications Abdelkérim Ousman
Université du Québec à Montréal
1 shared publication- Adriana Aguilar-Mahecha
Gerald Bronfman Department of Oncology, Jewish General Hospital, McGill University, Montreal, QC H4A 3T2, Canada
1 shared publication
Latest Publications
- 19 February 2023
- Published by Elsevier in Social Science & Medicine
- Vol. 324, 115789
Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics
- 19 February 2023
- Published by Elsevier in Social Science & Medicine
- Vol. 324, 115789
Organizing precision medicine: A case study of Memorial Sloan Kettering Cancer Center's engagement in/with genomics
- 1 July 2022
- Published by Elsevier in Social Science & Medicine
- Vol. 304, 112317
Multi-polar scripts: Techno-regulatory environments and the rise of precision oncology diagnostic tests
- 1 July 2022
- Published by Elsevier in Social Science & Medicine
- Vol. 304, 112317
Multi-polar scripts: Techno-regulatory environments and the rise of precision oncology diagnostic tests
- 4 December 2017
- Published by Springer Nature in History and Philosophy of the Life Sciences
- Vol. 40 (1) , 12
Correction to: Informing materials: drugs as tools for exploring cancer mechanisms and pathways
The original version of this article unfortunately contained a mistake. Three entries are incorrect in the reference list. The corrected references are given below.
- 4 December 2017
- Published by Springer Nature in History and Philosophy of the Life Sciences
- Vol. 40 (1) , 12
Correction to: Informing materials: drugs as tools for exploring cancer mechanisms and pathways
The original version of this article unfortunately contained a mistake. Three entries are incorrect in the reference list. The corrected references are given below.
- 18 May 2017
- Published by Springer Nature in History and Philosophy of the Life Sciences
- Vol. 39 (2) , 1-23
Informing materials: drugs as tools for exploring cancer mechanisms and pathways
This paper builds on previous work that investigated anticancer drugs as ‘informed materials’, i.e., substances that undergo an informational enrichment that situates them in a dense relational web of qualifications and measurements generated by clinical experiments and clinical trials. The paper analyzes the recent transformation of anticancer drugs from ‘informed’ to ‘informing material’. Briefly put: in the post-genomic era, anti-cancer drugs have become instruments for the production of new biological, pathological, and therapeutic insights into the underlying etiology and evolution of cancer. Genomic platforms characterize individual patients’ tumors based on their mutational landscapes. As part of this new approach, drugs targeting specific mutations transcend informational enrichment to become tools for informing (and destabilizing) their targets, while also problematizing the very notion of a ‘target’. In other words, they have become tools for the exploration of cancer pathways and mechanisms. While several studies in the philosophy and history of biomedicine have called attention to the heuristic relevance and experimental use of drugs, few have investigated concrete instances of this role of drugs in clinical research.
- 18 May 2017
- Published by Springer Nature in History and Philosophy of the Life Sciences
- Vol. 39 (2) , 1-23
Informing materials: drugs as tools for exploring cancer mechanisms and pathways
This paper builds on previous work that investigated anticancer drugs as ‘informed materials’, i.e., substances that undergo an informational enrichment that situates them in a dense relational web of qualifications and measurements generated by clinical experiments and clinical trials. The paper analyzes the recent transformation of anticancer drugs from ‘informed’ to ‘informing material’. Briefly put: in the post-genomic era, anti-cancer drugs have become instruments for the production of new biological, pathological, and therapeutic insights into the underlying etiology and evolution of cancer. Genomic platforms characterize individual patients’ tumors based on their mutational landscapes. As part of this new approach, drugs targeting specific mutations transcend informational enrichment to become tools for informing (and destabilizing) their targets, while also problematizing the very notion of a ‘target’. In other words, they have become tools for the exploration of cancer pathways and mechanisms. While several studies in the philosophy and history of biomedicine have called attention to the heuristic relevance and experimental use of drugs, few have investigated concrete instances of this role of drugs in clinical research.
- Open Access
- 1 September 2014
- Published by JLE in Sciences sociales et santé
- Vol. 32 (3) , 13-42
Régimes thérapeutiques et dispositifs de preuve en oncologie : l’organisation des essais cliniques, des groupes coopérateurs aux consortiums de recherche
- 1 September 2014
- Published by JLE in Sciences sociales et santé
- Vol. 32 (3) , 13-42
Open AccessRégimes thérapeutiques et dispositifs de preuve en oncologie : l’organisation des essais cliniques, des groupes coopérateurs aux consortiums de recherche
- 1 June 2014
- Published by Elsevier in Social Science & Medicine
- Vol. 111, 74-83
Testing devices or experimental systems? Cancer clinical trials take the genomic turn
- 1 June 2014
- Published by Elsevier in Social Science & Medicine
- Vol. 111, 74-83
Testing devices or experimental systems? Cancer clinical trials take the genomic turn
- 18 February 2014
- Published by Springer Nature
Cancer Research and Protocol Patients
- 1 December 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9909) , e45-e46
21st-century oncology: a tangled web
- 1 December 2013
- Published by Elsevier in The Lancet
- Vol. 382 (9909) , e45-e46
21st-century oncology: a tangled web
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 4, 58
Therapy’s Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy
This article traces the history of research on resistance to drug therapy in oncology using scientometric techniques and qualitative analysis. Using co-citation analysis, we generate maps to visualize subdomains in resistance research in two time periods, 1975-1990 and 1995-2010. These maps reveal two historical trends in resistance research: first, a shift in focus from generic mechanisms of resistance to chemotherapy to a focus on resistance to targeted therapies and molecular mechanisms of oncogenesis; and second, a movement away from an almost exclusive reliance on animal and cell models and towards the generation of knowledge about resistance through clinical trial work. A close reading of highly cited articles within each subdomain cluster reveals specific points of transition from one regime to the other, in particular the failure of several promising theories of resistance to be translated into clinical insights and the emergence of interest in resistance to a new generation of targeted agents such as imatinib and trastuzumab. We argue that the study of resistance in the oncology field has thus become more integrated with research into cancer therapy—rather than constituting it as a separate domain of study, as it has done in the past, contemporary research treats resistance as the flip side to treatment, as therapy’s shadow.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 4, 58
Open AccessTherapy’s Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy
This article traces the history of research on resistance to drug therapy in oncology using scientometric techniques and qualitative analysis. Using co-citation analysis, we generate maps to visualize subdomains in resistance research in two time periods, 1975-1990 and 1995-2010. These maps reveal two historical trends in resistance research: first, a shift in focus from generic mechanisms of resistance to chemotherapy to a focus on resistance to targeted therapies and molecular mechanisms of oncogenesis; and second, a movement away from an almost exclusive reliance on animal and cell models and towards the generation of knowledge about resistance through clinical trial work. A close reading of highly cited articles within each subdomain cluster reveals specific points of transition from one regime to the other, in particular the failure of several promising theories of resistance to be translated into clinical insights and the emergence of interest in resistance to a new generation of targeted agents such as imatinib and trastuzumab. We argue that the study of resistance in the oncology field has thus become more integrated with research into cancer therapy—rather than constituting it as a separate domain of study, as it has done in the past, contemporary research treats resistance as the flip side to treatment, as therapy’s shadow.
- 1 March 2012
- Published by Elsevier in Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences
- Vol. 43 (1) , 37-51
Too many numbers: Microarrays in clinical cancer research
- 1 March 2012
- Published by Elsevier in Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences
- Vol. 43 (1) , 37-51
Too many numbers: Microarrays in clinical cancer research